ProMIS Neurosciences EV / EBITDA
Cos'è EV / EBITDA di ProMIS Neurosciences?
EV / EBITDA di ProMIS Neurosciences, Inc. è N/A
Qual è la definizione di EV / EBITDA?
EV / EBITDA è il valore aziendale diviso per guadagni prima di interessi, tasse, deprezzamento e ammortamento. È una misura di quanto sia costosa una azione ed è più frequentemente valida per i confronti tra le aziende rispetto al rapporto prezzo / guadagno. Misura il prezzo (sotto forma di valore d'impresa) che un investitore paga a vantaggio del flusso di cassa della società (sotto forma di EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA di aziende nel Health Care settore su TSX rispetto a ProMIS Neurosciences
Cosa fa ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Aziende con ev / ebitda simili a ProMIS Neurosciences
- Cashrewards ha EV / EBITDA di N/A
- Cosmo Lady (China) ha EV / EBITDA di N/A
- Moiselle International ha EV / EBITDA di N/A
- Atacama Copper ha EV / EBITDA di N/A
- Stellar AfricaGold ha EV / EBITDA di N/A
- XpresSpa Inc ha EV / EBITDA di N/A
- ProMIS Neurosciences ha EV / EBITDA di N/A
- Genetic Technologies ha EV / EBITDA di N/A
- Mammoth Services Inc ha EV / EBITDA di N/A
- Rua Life Sciences Plc ha EV / EBITDA di N/A
- Europlasma S.A ha EV / EBITDA di N/A
- Voleo Trading Systems Inc ha EV / EBITDA di N/A
- Tuktu Resources Ltd ha EV / EBITDA di N/A